Related Experiment Videos
Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma
Sing Yu Goldstein-Jackson1, Georg Gosheger, Günter Delling
1Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Albert-Schweitzer-Str. 33, 48149, Germany.
Journal of Cancer Research and Clinical Oncology
|May 27, 2005
Summary
Extraskeletal osteosarcoma (ESOS) patients treated with multi-agent chemotherapy and surgery showed a surprisingly good survival rate. This combined approach is recommended for treating ESOS.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Extraskeletal osteosarcoma (ESOS) is a rare bone cancer variant.
- Understanding ESOS clinical features and treatment outcomes is crucial for patient management.
Purpose of the Study:
- To investigate the clinical characteristics of extraskeletal osteosarcoma (ESOS).
- To evaluate the treatment outcomes of ESOS patients receiving multi-modal therapy.
Main Methods:
- Retrospective analysis of the co-operative osteosarcoma study-group database.
- Inclusion of patients with ESOS, analyzing patient, tumor, and treatment variables.
- Treatment comprised surgery and multi-agent chemotherapy, similar to conventional osteosarcoma.
Main Results:
- Seventeen ESOS patients were analyzed; the thigh was the most common tumor site.
- Median follow-up was 3.2 years, with 3-year overall and event-free survival rates of 77% and 56%, respectively.
- Complete surgical remission was associated with improved overall survival (P = 0.0004).
Conclusions:
- ESOS patients in this study demonstrated favorable survival rates.
- The combination of multi-agent chemotherapy and surgery may contribute to improved outcomes.
- This multi-modal treatment approach is recommended for ESOS management.